JPRN-UMIN000008140已完成2 期
A phase II study of Paclitaxel combined with Bevacizumab in HER2 negative metastatic Breast Cancer - KBCOG 12
Kobe Breast Cancer Oncology Group0 个研究点目标入组 24 人开始时间: 2012年6月12日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) Previously treated with bevacizumab 2) Primary chemotherapy refractory with Paclitaxel 3) The operation has been scheduled for the examination period 4) Uncontrollable hypertension 5) Symptomatic brain metastasis 6) Anaphylaxis against drugs used in protocol treatment 7) Uncontrollable ascites, pleural effusion 8) Active infection, Severe complications (abnormal electrocardiogram, heart failure, arrhythmia, thromboembolism, etc) 9) Severe infection or serious complications, such as hypoalimentation 10) Other active malignancies 11) Pregnant or nursing women or women who like be pregnant and men with partner willing to get pregnant 12) Doctors decision for exclusion
研究者
相似试验
招募中
2 期
Phase II study of a Combination of Paclitaxel and 5'-DFUR in Patients with S-1 Failure Unresectable or Recurrent Gastric CancerAdvanced or recurrent gastric cancer previously treated with S-1JPRN-UMIN000008632Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine35
招募中
4 期
Observational study of paclitaxel with Bevacizumab for advanced or recurrent breast cancer(SBCCSG-28)advanced or recurrent breast cancerJPRN-UMIN000009090Saitama Breast Cancer Clinical Study Group (SBCCSG)70
招募中
2 期
Phase II study of nab-paclitaxel in combination with carboplatin in patients with refractory small-cell lung cancerRefractory small-cell lung cancerJPRN-UMIN000015565Dokkyo Medical University22
招募中
不适用
Phase II Study of Paclitaxel in Combination with Carboplatin in Patients With Stage IB-II Cervical Cancer.cervical cancerJPRN-UMIN000012400Department of Obstetrics and Gynecology, Osaka Medical College30
已完成
2 期
A phase II study of Bevacizumab plus Paclitaxel followed by Eribulin maintenance therapy in patients with HER2-negative metastatic breast cancer.HER2-negative metastatic breast cancerJPRN-UMIN000015971Sairtama Breast Cancer Clinical Study Group (SBCCSG)51